A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Veliflapon (DG-031) in Reducing the Risk of Acute Cardiovascular Events in African American Patients With Coronary Artery Disease(The LTCAD Study).
Phase of Trial: Phase III
Latest Information Update: 28 Nov 2006
At a glance
- Drugs Veliflapon (Primary)
- Indications Myocardial infarction; Stroke
- Focus Therapeutic Use
- Acronyms LTCAD
- Sponsors deCODE genetics
- 09 Jun 2006 New trial record.